Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
This grant program supports research proposals aimed at evaluating outcomes associated with the use of Aztreonam–Avibactam (ATM-AVI) in real-world clinical settings among patients with suspected or documented infections caused by aerobic gram-negative organisms.
Característiques principals
Clinical Area of Interest: Infectious Disease – Bacterial – RES

Proposals should address all of the following outcomes:
  • Clinical effectiveness with ATM-AVI
  • Safety outcomes with ATM-AVI
  • Microbiological outcomes with ATM-AVI
  • Health Economic outcomes with ATM-AVI
    • Lloc de presentació
    HMRIB and PSMAR staff who need more information should contact:
    Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: [email protected] Ext.: 1670
    Marta López: [email protected] Ext.: 1576
    Júlia Vidal: [email protected] Ext.: 1736
    Convocatòria (URL)
    https://cdn.pfizer.com/pfizercom/2026-03/2026%20I&I%20G%20ATM-AVI%20RES_final.pdf
    Requisits
  • The geographical scope is limited to countries where ATM-AVI is available (ex-US) and used in clinical practice, including but not limited to parts of EU, the United Kingdom, the Middle East, and selected Asia-Pacific markets.
  • The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy.
  • Only organizations can receive grants; individuals are not eligible.
  • For collaborative projects, whether within a single institution or across multiple organizations, all partners must have relevant roles, and the requesting organization must play a key role.
  • The applicant must be the project/program lead—or an authorized designee—and must be an employee or contractor of the requesting organization.
    • Dotació
    $50,000
    Durada
    12 months

    Arxius

    Arxiu
    2026-I&I-G-ATM-AVI-RES.pdf